Search Results
Showing 12 of 12 results
Straight Out of High School How Teva Develops the Next Generation of Professionals
Meta description An educational program in our Opava Czech Republic site is bringing together Teva s professionals and high schoolers
Teva goes to University Collaborating with Academia to Improve the Lives of Patients
Ongoing academic partnerships are the driving forces behind some of Teva s dynamic Research Development
New Trends in Advanced Analytics and AI for Patient Care
Data scientist Michal Melamed discusses the innovations she s most excited about in healthcare technology
Meet the Expert Ivana Šoljić Jerbić
Ivana Šoljić Jerbić lead scientist in the development of complex sterile medicines at Teva Croatia talks about her work collaborating with people all over the world Read more
Meet Our People Gregg DeRosa
Gregg DeRosa who leads Teva s Global Clinical Operations talks with us about his leadership style and more
Generic Medicines and Regulation Producing the World s Biggest Medicine Cabinet Safely and Effectively
Generic medicines are created to be the same as branded drugs whose patents have expired using the same active ingredients and producing the same clinical effects We explain how these more affordable versions of branded drugs are regulated to ensure that they are safe and effective
Generics R D
Teva s Global R D organization is devoted to the development of new medicines devices and combination products that provide meaningful therapeutic benefit
Where Big Pharma Meets Academia Key Trends I m Watching
Dana Bar On Head of Global Academic Collaborations at Teva Global R D showcases the innovative ways pharmaceutical companies and academic institutions are collaborating to define the future of drug development
Meet the Expert Boglárka Szabóné Szikszai
Boglárka Szabóné Szikszai and her team are responsible for developing new and existing Active Pharmaceutical Ingredients in Teva s site in Debrecen Hungary
Meet the Expert Barak Zohar
Barak talks about his work developing biosimilars at Teva and how his curiosity drives him every day
Can AI driven digital biomarkers redefine diagnostics and clinical trials
Artificial Intelligence and advanced analytics technologies have huge potential to improve the world of health We talk to Teva employees who are using the technologies
Our goal is to lead the field of biosimilars just like we lead in generic medicines
Dr Nir Shapir VP of Teva s global research and development team and CMC Biosimilars division discusses Teva s entry into the biosimilars market and the complexity of manufacturing biopharmaceuticals Read the interview with Haaretz reprinted with permission
